CD22 and precursor B-cell acute lymphoblastic leukemia: The underlying malignancies included T-acute lymphoblastic leukemia (ALL) (n = 1), diffuse large B cell lymphoma (DLBCL) (n = 4), and B-ALL (n = 3), and in accordance with it, CAR-T cells targeting CD7, CD19, and CD22 were infused, respectively.